Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01IWS
|
|||
| Former ID |
DAP001304
|
|||
| Drug Name |
Inulin
|
|||
| Synonyms |
Inulin [BAN]; Inulin and sodium chloride; Inulin from Jerusalem artichokes; Inulin USP 27
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Measure kidney function [ICD-11: MG02; ICD-10: N00-N39] | Approved | [1] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C228H382O191
|
|||
| Canonical SMILES |
C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)COC3(C(C(C(O3)CO)O)O)COC4(C(C(C(O4)CO)O)O)COC5(C(C(C(O5)CO)O)O)COC6(C(C(C(O6)CO)O)O)COC7(C(C(C(O7)CO)O)O)COC8(C(C(C(O8)CO)O)O)COC9(C(C(C(O9)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)CO)O)O)O)O
|
|||
| InChI |
1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1
|
|||
| InChIKey |
JYJIGFIDKWBXDU-MNNPPOADSA-N
|
|||
| CAS Number |
CAS 9005-80-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Alistipes shahii
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Alistipes shahii was increased by Inulin (p < 0.05). | |||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Renal dialysis | |||
| Description | The abundance of Bacteroides was increased by Inulin (p = 0.03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Bifidobacterium was increased by Inulin (p < 0.0001). | |||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was increased by Inulin (p < 0.05). | |||
|
Studied Microbe: Bifidobacterium animalis
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | BALB/c mice | Experimental Sample | Faeces | |
| Disease or Condition | Acute leukemia | |||
| Description | The abundance of Bifidobacterium animalis was increased by Inulin. | |||
|
Studied Microbe: Bifidobacterium sp.
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | BALB/c mice | Experimental Sample | Faeces | |
| Disease or Condition | Acute leukemia | |||
| Description | The abundance of Bifidobacterium sp. was decreased by Inulin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfovibrionales | ||||
|
Studied Microbe: Bilophila
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Bilophila was decreased by Inulin (p < 0.001). | |||
|
Studied Microbe: Desulfovibrionaceae
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | BALB/c mice | Experimental Sample | Faeces | |
| Disease or Condition | Acute leukemia | |||
| Description | The abundance of Desulfovibrionaceae was decreased by Inulin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Anaerostipes
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Anaerostipes was increased by Inulin (p < 0.0001). | |||
|
Studied Microbe: Anaerostipes hadrus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Anaerostipes hadrus was increased by Inulin (p < 0.05). | |||
|
Studied Microbe: Roseburia sp.
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | BALB/c mice | Experimental Sample | Faeces | |
| Disease or Condition | Acute leukemia | |||
| Description | The abundance of Roseburia sp. was increased by Inulin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Renal dialysis | |||
| Description | The abundance of Akkermansia was increased by Inulin (p = 0.045). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Renal dialysis | |||
| Description | The abundance of Bacteroidetes was increased by Inulin (p = 0.04). | |||
|
Studied Microbe: Verrucomicrobia
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Renal dialysis | |||
| Description | The abundance of Verrucomicrobia was increased by Inulin (p = 0.045). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Flexibility of Gut Microbiota in Ageing Individuals during Dietary Fiber Long-Chain Inulin Intake. Mol Nutr Food Res. 2021 Feb;65(4):e2000390. | |||
| REF 3 | Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study. J Ren Nutr. 2021 Sep;31(5):512-522. | |||
| REF 4 | Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut. 2017 Nov;66(11):1968-1974. | |||
| REF 5 | Non Digestible Oligosaccharides Modulate the Gut Microbiota to Control the Development of Leukemia and Associated Cachexia in Mice. PLoS One. 2015 Jun 22;10(6):e0131009. | |||
| REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.